medRxiv preprint doi: https://doi.org/10.1101/2022.08.21.22279038; this version posted September 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint in the certain sector of the se

perpetuity. It is made available under a CC-BY-ND 4.0 International license .



MDPI

Type of the Paper (Article, Review, Communication, etc.)

# A pilot analysis of circulating cfRNA transcripts for the detection of lung cancer

8

9

10

11

12

13

14

15 16

31 32

33

1

Chamindi Seneviratne <sup>1,2</sup> , Amol C. Shetty <sup>2</sup> , Xinyan Geng <sup>3</sup> , Carrie McCracken <sup>2</sup> , Jessica Cornell <sup>1</sup> , Kris-	
tin Mullins <sup>3,4</sup> , Feng Jiang <sup>3</sup> , and Sanford Stass <sup>3,4,*</sup>	

- <sup>1</sup>Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD; <u>csenevi@som.umaryland.edu</u>; <u>JCor-nell@som.umaryland.edu</u>
- <sup>2</sup>The Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD; <u>AShetty@som.umaryland.edu</u>; <u>csenevi@som.umaryland.edu</u>; <u>csenevi@som.umaryland.edu</u>;
- <sup>3</sup>Department of Pathology, University of Maryland School of Medicine, Baltimore, MD; <u>kmullins@som.umaryland.edu</u>; <u>FJiang@som.umaryland.edu</u>; <u>SStass@som.umaryland.edu</u>
- <sup>4</sup>Laboratories of Pathology, University of Maryland Medical Center, Baltimore, MD; <u>kmullins@som.umaryland.edu</u>; <u>SStass@som.umaryland.edu</u>
- \* Correspondence: <u>SStass@som.umaryland.edu</u>

17 Abstract: Lung cancers are the leading cause of cancer-related deaths worldwide. Studies have shown that nonsmall cell lung cancer (NSCLC) which constitutes majority of lung cancers, are significantly more responsive to 18 early-stage interventions. However, the early stages are often asymptomatic, and current diagnostic methods 19 are limited in their precision and safety. The cell-free RNAs (cfRNA) circulating in plasma (Liquid biopsies) offer 20 non-invasive detection of spatial and temporal changes occurring in primary tumors since early stages. To ad-21 dress gaps in current cfRNA knowledgebase, we conducted a pilot study for comprehensive analysis of tran-22 scriptome-wide changes in plasma cfRNA in NSCLC patients. Total cfRNA was extracted from archived plasma 23 collected from NSCLC patients (N=12), cancer-free former smokers (N=12) and non-smoking healthy volunteers 24 (N=12). Plasma cfRNA expression levels were quantified by using a tagmentation-based library preparation and 25 sequencing. The comparisons of cfRNA expression levels between patients and the two control groups revealed 26 a total of 2357 differentially expressed cfRNA enriched in 123 pathways. Of these, 251 transcripts were previ-27 ously reported in primary NSCLCs. A small subset of genes (N=5) was validated in an independent sample 28 (N=50) using qRT-PCR. Our study provides a framework for developing blood-based assays for early detection 29 of NSCLC and warrants further validation. 30

Keywords: NSCLC; cell-free RNA; liquid biopsies; biomarkers; smokers; plasma; circulating RNA

# 1. Introduction

Lung cancers are the leading cause of cancer-related deaths in both men and women in the U.S. 34 and worldwide. Non-small cell lung cancer (NSCLC) constitutes approximately 84% of all lung cancer 35 cases, and consists of two main histological subtypes: adenocarcinoma (AC) and squamous cell carci-36 noma (SCC) [1]. The main risk factor for developing NSCLC is smoking, which is preventable, yet 37 highly prevalent with over a billion smokers around the world [2]. Moreover, smoking, and other en-38 vironmental pollutants interact with biological factors such as aging and genetic risk variants to in-39 crease disease burden [3-6]. Furthermore, the NSCLC risk has been shown to correlate positively with 40 severity and duration of smoking, and negatively with time since smoking cessation [7, 8]. 41

Because the lung cancers are often asymptomatic in early stages, most patients are diagnosed at advanced stages resulting in only about 15-20% of patients surviving 5 years after the diagnosis [6]. The early-stage NSCLC are more responsive to treatment [9], and therefore, crucial to reduce mortality. At protect the diagnostic curve dark in the state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark is a state of the diagnostic curve dark in the diagnostic curve dark in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Diagnostics 2022, 12, x FOR PEER REVIEW

2 of 18

with low dose computed tomography (LDCT) [10]. In fact, based on data from Cancer Intervention and 46 Surveillance Modeling Network (CISNET), the US Preventive Services Task Force (USPSTF) recom-47 mended annual screening of adults aged 50 to 80 years of age with a smoking history of 20 or more 48 pack-years, who currently smoke or quit smoking within the past 15 years [11]. This 2021 USPSTF rec-49 ommendation (A-50-80-20-15) was updated to expand the population eligible for LDCT screening over 50 the previous 2013 USPSTF recommendation that required smoking history of 30 or more pack-years 51 (A-50-80-30-15). The LDCT has high negative predictive values, moderate sensitivity and specificity, 52 and low positive predictive values [12]. A recent meta-analysis corresponding to data from 84,558 par-53 ticipants who had a smoking history 15 or more pack-years indicated a 17% relative reduction in mor-54 tality in the group screened with LDCT compared to the control group [12]. Despite these encouraging 55 statistics, there are several important limitations to using LDCT for NSCLC diagnosis. For example, the 56 high false-positive rates can lead to further testing of benign PNs with invasive diagnostic and thera-57 peutic procedures such as serial CTs, biopsy and surgery that carry their own morbidity. The invasive 58 procedures are reported to be performed in 44% of smokers with indeterminate PNs that have roughly 59 5% probability of malignancy, and 35% of surgical resections are ultimately determined to be benign 60 diseases [13]. Another concern is the exposure to radiation with repeated LDCT. Statistical modelling 61 has predicted 1 death for every 13.0 lung-cancer related deaths avoided by LDCT with 2021 USPSTF 62 recommendations, which was a 2% worsening compared to risk associated with 2013 USPSTF recom-63 mendations[11]. Considering these factors, it is clinically important to develop noninvasive biomarkers 64 to distinguish malignant from benign PNs facilitating positive screening results on LDCT. 65

Recently, the concept of liquid biopsies has garnered excitement among the scientific community 66 for its' potential to provide real-time information on spatial and temporal changes in tumor markers in 67 an easily obtained peripheral blood sample [14]. Several types of biomarkers have been explored in 68 liquid biopsies as potential diagnostics with mixed results. Circulating tumor DNAs (ctDNA) have over 69 90% sensitivity and specificity for NSCLC diagnosis in patients with stage II–IV NSCLC, but around 70 50% in patients with stage I NSCLC when shedding rates are low [15]. Analysis of mutations in ctDNA 71 has also been reported to have lower sensitivity and specificity in early-stage NSCLC [16]. Therefore, 72 analysis of ctDNA-mutations or quantities appear to be more suitable for therapeutic and disease mon-73 itoring in NSCLC patients, rather than the early detection. In contrast, tumors with low shedding rates 74 add cell-free RNAs (cfRNA) to blood circulation presenting with the opportunity to identify the over-75 expressed, tumor-specific, and tumor-derived RNA signals in the blood [17] at early stages, potentially 76 facilitating high rates of patients able to receive curative surgical resections. Studies have also shown 77 that cfRNA could complement ctDNA and thus improve early diagnosis [18]. The studies of cfRNA 78 have mainly focused on either microRNAs (miRNA) or a small number of known cancer-related mes-79 senger RNAs (mRNA)[19-21]. Moreover, the published studies have used large amounts of plasma – 80 up to 4-5ml, for cfRNA extraction for expression analyses limiting its potential clinical use. We have 81 conducted a pilot study to explore the ability to detect cfRNA signatures of NSCLC, particularly of the 82 genes that were previously reported to be differentially expressed in lung cancer primary tissue biop-83 sies, compared to both cancer-free smokers and healthy non-smokers. 84

# 2. Materials and Methods

85

Study design: In this pilot study, we first compared the expression levels of plasma cfRNA obtained 86 from SCC and AC patients (N=12; cases) and cancer-free former smokers (N=12; control\_smokers). As 87 all patients in the case group were also heavy smokers, we included a second control group of non-88 smoking healthy individuals (N=12; control\_healthy) to exclude differentially expressed cfRNAs asso-89 ciated with smoking, rather than pathological processes underlying NSCLC. Each participant provided 90 whole blood samples as part of an umbrella protocol approved by the Institutional Review Board of 91 the University of Maryland Baltimore [UMB IRB protocol ID: HP-00040666] and the Veterans Affairs 92 Maryland Health Care System. All participants provided written informed consent to participate in 93 research conducted at the University of Maryland Medical Center and the Baltimore VA Medical Cen-94 ter. Diagnosis of lung cancer was established by pathologic examination of tissues obtained via surgery 95 or biopsy. Histological diagnosis was made on bronchoscopic biopsy specimens and thoracotomy 96

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Diagnostics 2022, 12, x FOR PEER REVIEW

according to the World Health Organization (WHO) categories. The NSCLC stage classification was 97 based on WHO classification and the International Association for the Study of Lung Cancer staging 98 system. The smokers consisted of former smokers who had a minimum smoking history of 30-pack 99 years and quit within the past 15 years. Exclusion criteria were similar to Leng et al. 2017 [8]. Demo-100 graphic and clinical characteristics of the cohorts are presented in Table 1. 101

	Cases	Control_ Smokers	Control_ Healthy		value ses vs.	p-value Smokers vs.
		Sinokers	Tleatury	Control_	Control_	Healthy
				Smokers	Healthy	
Discovery cohort (N	N=36):					÷
Sample size	12	12	12			
Age (mean, (SD))	67.17 (8.99)	68.44 (10.01)	40.17 (4.99)	0.728	< 0.0001	< 0.0001
Gender (Male, N (%))	11 (91.67)	9 (75)	7 (58.33)	0.3144	0.0480	0.3144
Race (Caucasian, N (%))	5 (4.67)	5 (4.67)	5 (4.67)	ns	ns	ns
Stage						
Stage I (N)	7 (AC=5)					
Stage II (N)	4 (AC=1)					
Stage III-IV (N)	1 (AC=0)					
Histological type						
AC (N)	6					
SCC (N)	6					
Average plasma volumes used (ml)	1.6	1.6	1.54	ns	ns	ns
Validation cohort (1	N=50):	1		•	- 1	
Sample size	25	18	7			
Age (mean, (SD))	64.60 (8.97)	61.28 (10.23)	58.14(17.38)	ns	ns	ns
Gender (Male, N (%))	19 (76.00)	13 (72.22)	5 (71.43)	ns	ns	ns
Race (Caucasian, N (%))	52 (50.99)	11 (61.11)	3 (60.00)	ns	ns	ns
Stage						
Stage I (N)	4 (AC=2)					
Stage II (N)	2 (AC=0)					
Stage III-IV (N)	9 (AC=8)					
Missing data	10 (AC=7)					
Histological type						
AC (N)	13		ľ			
SCC (N)	12					
Average plasma volumes used (ml)	0.5	0.5	0.5			

Table 1: Demographic and clinical characteristics

ns – not significant (p>0.05); AC – adenocarcinoma; SCC – squamous cell carcinoma.

Sample preparation and sequencing: Archived plasma samples (volumes given in Table 1) prepared106from 3-6 mL of whole blood collected into tubes containing EDTA were thawed at 37°C and centrifuged107at 16,000 x G for 30 minutes at 4°C to remove any cellular components in plasma. The supernatant was108

102

103

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

#### Diagnostics 2022, 12, x FOR PEER REVIEW

4 of 18

122

136

extracted and centrifuged again at 13,000 x G for 30 minutes at 4°C, and store at -80°C until day of 109 cfRNA extractions. Quality control procedures for plasma sample preparation were similar to our ear-110 lier study[22]. The cfRNA was extracted from archived plasma using the miRNeasy® Serum/Plasma 111 Advanced Kit (Qiagen) according to manufacturer's guidelines and were tested for RNA integrity us-112 ing an Agilent bioanalyzer system. Libraries were prepared using a tagmentation-based method con-113 sisting of a two-step probe-assisted exome enrichment for cfRNA detection (Illumina, Inc, San Diego, 114 CA) [23]. An Illumina Exome enrichment panel that included > 425,000 probes (oligos), each con-115 structed against the NCBI37/hg19 reference genome, covering > 98% of the RefSeq exome was used to 116 pool libraries with target cfRNA of interest. The probe set was designed to capture > 214,000 targets, 117 spanning 21,415 genes of interest. Probes hybridized to target libraries were captured according to pro-118 tocol and amplified using a 19-cycle PCR program. Enriched libraries were then purified with magnetic 119 beads and were then sequenced using a NovaSeq 6000 system (Illumina, Inc), at a sequencing depth of 120 100 million reads at 100bp PE length sequences. 121

Sequencing data analyses: Raw sequence reads generated for each sample were analyzed using the 123 CAVERN analysis pipeline [24]. Read quality was assessed using the FastQC toolkit to ensure good 124 quality reads for downstream analyses. Reads were aligned to the Human reference genome GRCh38 125 (available from *Ensembl* repository) using HISAT2, a fast splice-aware aligner for mapping next-gener-126 ation sequencing reads [25]. Reads were aligned using default parameters to generate the alignment 127 BAM files. Read alignments were assessed to compute gene expression counts for each gene using the 128 HTSeq count tool [26] and the Human reference annotation (GRCh38). The raw read counts were nor-129 malized for library size and dispersion of gene expression. The normalized counts were utilized to 130 assess differential cfRNA expression between conditions using DESeq2. P-values were generated using 131 Wald test implemented in DESeq2 and then corrected for multiple hypothesis testing using the Benja-132 mini-Hochberg correction method [27]. Significant differentially expressed cfRNA between conditions 133 were determined using a false discovery rate (FDR) of 5% and a minimum absolute log2(fold-change) 134 of 1. 135

Quantitative RT-PCR (qRT-PCR) for validation of a subset of cfRNA: Based on findings from se-137 quencing data analysis, we selected five differentially expressed protein coding genes as listed in Table 138 1 and detailed below in the results section for validation assays. We assessed the abundance of cfRNA 139 for the five selected genes using qRT-PCR in an independent set of plasma samples from 25 cases 140 (AC=13; SCC=12) and 25 controls (control\_smokers=18; control\_healthy=7). The demographic and clin-141 ical characteristics of the validation cohort are presented in Table 1. Total cfRNA was extracted from 142 archived plasma (500ul per sample) using the same protocol described above for the discovery cohort. 143 A mixture of three commercially available RNA spike-ins (miRNAs UniSp2, UniSp4 and UniSp5) from 144the RNA Spike-In Kit, For RT were added to plasma samples according to the manufacture's protocol 145 (Qiagen, Germantown, MD, USA) prior to extraction of cfRNA to control for cfRNA isolation across 146 samples. The extracted total cfRNA samples were then split into equal volumes for cDNA synthesis 147 and subsequent mRNA quantification and detection of the three-miRNA spike-ins in parallel. We used 148 miRCURY LNA RT and miRCURY LNA SYBR Green PCR kits (Qiagen) for reverse transcription and 149 qPCR of spike-in miRNAs, and the QuantiTect® Reverse Transcription and QuantiTect SYBR Green RT-150 PCR kits (Qiagen) for reverse transcription and qPCR of the selected protein coding genes. All qPCR 151 reactions were performed in triplicates with 1:10 cDNA dilutions on a Bio-Rad CFX real-time PCR de-152 tection system (Bio-Rad, Hercules, California, USA), according to protocols associated with each kit. As 153 stable endogenous reference genes for quantifying circulating mRNA in plasma samples have not been 154 established in literature and normalizing to a global mean of all expressed mRNA was not applicable 155 to the analysis of five genes, we opted for not using a reference gene in this pilot study. We also explored 156 the possibility of using GAPDH - the commonly used endogenous reference gene for cellular mRNA 157 and did not detect any amplification. Therefore, we adopted a method of first assessing the between 158 sample variability using three spike-ins to identify outlier samples, and then perform qRT-PCR for the 159

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Diagnostics 2022, 12, x FOR PEER REVIEW

5 of 18

five selected genes excluding outliers. Two tailed t-tests in GraphPad Prism software (San Diego, CA, USA) were performed for statistical comparisons.

### 3. Results

cfRNA processing and quality control: cfRNA was extracted from all 36 samples at mean concentra-163 tions of 0.111 ng/ul in cases, 0.085 ng/ul in control\_smokers, and 0.151ng/ul in control\_healthy group. 164The RNA integrity numbers (RIN) ranged from 1 to 5.3. All samples had sequence reads that mapped 165 >80% to the reference sequence and mapped to exonic regions. Total Gene Abundance ranged from 166 approximately 10 to 70 million. Of these genes, 0.5-10% were Hb coding genes, 0.5-20% mitochondrial 167 genes, <0.03% ribosomal RNA (rRNA) genes, and up to 4% were other non-coding RNA (ncRNA) 168 genes. Amongst protein coding genes, the most abundant were actin, myosin, platelet-specific genes, 169 and pseudogenes. 170

Identification of differentially expressed cfRNA between cases and controls: Differential expres-172 sion of cfRNA was analyzed after excluding Hb, Mitochondrial and rRNA transcripts. As shown in 173 Figure 1.1, a total of 1,905 (X+Y+Z) cfRNA were identified to be differentially expressed in plasma sam-174 ples from cases compared to the two control groups. Of these, 2 cfRNA (LINC01956 and TAS2R16) 175 were differentially expressed in opposite directions in cases compared to control\_smokers and con-176 trol\_healthy groups, and therefore we have included theses in both X and Z categories in Figure 1.1: 177 Both cfRNA were downregulated compared to control\_smokers and upregulated compared to con-178 trol\_healthy group. Another 1,377 (B+C+D in Figure 1.1) cfRNA that were detected in cases, were dif-179 ferentially expressed in the same direction in cancer-free smokers. The volcano plots for comparison of 180 cfRNA differential expression between cases and controls are presented in Figures 2.1 and 2.2. 181 Statistical power analysis: post-hoc power analysis revealed that the sample of 12 cases and 24 controls 182 afforded a 78.5% power to detect differentially expressed genes with 2-fold effect size using a 5% false 183 discovery rate. 184

Exploratory subgroup analysis: We performed two subgroup analyses exploring differentially ex-186 pressed cfRNA between (1) subtypes of cases - AC vs. SCC, and (2) based on NSCLC stage - stages 1 187 vs. 2, compared to both control groups irrespective of their statistical significance in the combined case 188 group. Figure 1.2 presents all cfRNA within each subtype category excluding DEGs shared with cancer-189 free smokers (i.e., comparisons between control smokers and control healthy groups). Of these, a total 190 of 452 cfRNA (64.3% all DEGs in Figure 1.2) were not detected in the combined cases (X+Y+Z in Figure 191 1.1), but uniquely differentially expressed in either AC or SCC, or both but in differing directions. As 192 depicted in Figure 1.3, nearly half of all 2357 total cfRNA (1905+452) were functional protein coding 193 genes (Figure 1.3). All cfRNA included in Figure 1 are listed in Supplementary Table 1. Similarly, Figure 194 1.4 presents cfRNA comparisons between NSCLC stages I and II, excluding cfRNA shared with cancer-195 free smokers. Comparisons with other NSCLC stages were not possible as we had only one sample 196 from a patient diagnosed with stage III and none for stage IV. Results indicated that 1,075 genes to be 197 expressed in plasma from patients who had stage 1 NSCLC (A+B+H+I+G+F in Figure 1.4), out of which 198 259 were common to both stages I and II. As both subgroup analyses had small numbers of patients 199 within each category (Table 1), these findings should only be considered as exploratory. 200

201

162

171

Diagnostics 2022, 12, x FOR PEER REVIEW




Figure 1: Distribution of NSCLC associated cfRNA. 1.1: cfRNA in plasma samples from cases 1.2: 204 cfRNA in subtypes AC and SCC. 1.3: Distribution of NSCLC associated cfRNA within functional cate-205 gories. The most common pseudogene subcategories were, processed\_pseudogenes (17.99%), unpro-206 cessed\_pseudogenes (2.89%), transcribed\_unprocessed\_pseudogenes (1.82%) and other subtypes were 207 present <1%. The "Other" category included the following subcategories at less than 1% abundance: 208 IG\_V\_genes, snoRNA, processed\_transcripts, TR\_V\_genes, TR\_J\_genes, sense\_intronic, misc\_RNA, 209 scaRNA, sense\_overlapping, IG\_C\_genes, TR\_C\_genes, 3prime\_overlapping\_ncRNA, IG\_J\_genes, 210 TEC, and TR\_D\_genes. 1.4: cfRNA within categories based on NSCLC stage. The numbers presented 211 in red and black color font in Figures 1.1, 1.2 and 1.3 represent up- and down-regulated genes, respec-212 tively. 213

Literature review to identify DEGs previously reported in primary NSCLC biopsies: We performed 215 an exhaustive review of all published studies listed on National Center for Biotechnology Information 216 (NCBI)'s database for gene-specific information, using gene IDs for each of the 2357 identified DEGs. 217 Studies reporting DEGs in primary NSCLC biopsies were identified and are referenced in Supplemen-218 tary Table 1. Our literature review showed that 10.65% of total DEGs (N=251 of 2357) have been reported 219 in primary tumor biopsies from NSCLC patients in published studies. Majority of these replicated 220 genes were mRNA transcripts of protein coding genes (N=174; 69.32%), while some (N=45; 17.92%) 221 were miRNA. Next, to assess inter-patient variation in cfRNA transcript abundance within each group 222 (i.e., combined cases, control\_smokers and control\_healthy), we evaluated whether the transcripts were 223 expressed above detectable levels, and then calculated coefficients of variation (%CV) within a group 224 for each gene. Of the total 174 replicated protein coding genes identified in this study, 78.97% were 225 expressed above threshold in cases and 88% had <50% CV for each replicated gene (Supplementary 226 Table 1). Fifteen cfRNA that were differentially expressed in cases compared to both control groups 227 (category "Y" in Figure 1.1) and reported in primary NSCLC tissue biopsies are listed in Table 2. The 228 distribution of these 15 replicated cfRNA that were differentially expressed in cases compared to the 229 two control groups are marked in volcano plots presented in Figure 2.1 and Figure 2.2. Of the six rep-230 licated protein coding genes, all but CCL17 were expressed with <50% CV in samples within cases 231


202 203

Diagnostics 2022, 12, x FOR PEER REVIEW

7 of 18

(Table 2 and Figure 3). Therefore, we selected the five genes (i.e., ARHGEF18, SRXN1, RAB38, 232 PDE4DIP, and BLID) for further validation in an independent cohort. 233

234



235 Figure 2: Volcano plots for (1) cases vs. smokers with benign PN (Figure 2.1), and (2) cases vs. healthy non-smokers (Figure 2.2). The horizontal dotted lines indicate an adjusted p-value of 0.05. The dots are colored blue or red if classified as down-or upregulated, respectively, using a threshold of log 2-fold 238 change of -1 and 1.

236 237

239

Diagnostics 2022, 12, x FOR PEER REVIEW

8 of 18

242

247







Figure 3: Distribution of read counts across individual samples for cfRNA of replicated protein coding 243 genes. Each dot represents cfRNA read counts for a given gene within individual samples. Red -genes 244 in cases; blue – smokers with benign PN; green – healthy non-smokers. The dotted line represents the 245 threshold for detecting read counts which was set at 3.4298. 246

Quantitative RT-PCR (qRT-PCR) for validation of replicated cfRNA of protein coding genes: While 248 all listed genes in Table 2 are reported to underly pathophysiology of NSCLC, we specifically selected 249 the protein coding genes for our initial validation as the circulating mRNA were the most abundant 250 type of cfRNA present in our discovery cohort, and cf-mRNA are relatively less characterized in liter-251 ature despite their biological relevance. Expression data for the three spike-ins in all 50 samples are 252 presented in Supplementary Figure 1. As UniSp2, UniSp4 and UniSp5 were detected in all samples, we 253 assessed cf-mRNA for the five genes in all 50 samples without excluding any. As shown in Figure 4, 254 our findings indicated that three of the five tested genes differentially expressed between cases and 255 controls. ARHGEF18 showed a nominally significant downregulation (i.e., higher Ct values) in cases 256 (p=0.037), and SRXN1 showed a trend towards downregulation in cases (p=0.056) compared to the 257 combined control group. PDE4DIP showed a trend towards downregulation in cases compared only to 258 the healthy non-smokers (p=0.079). The other two genes -RAB38 and BLID, did not show statistically 259 significantly expressed cfRNA levels between cases and controls. 260










Figure 4: qRT-PCR analysis of changes in the expression levels of cfRNA of selective protein coding genes in an independent sample. Each symbol represents log transformed Ct values of mRNA levels within each sample averaged across three technical repeats. The horizontal lines represent mean expression levels within each group.





Gene.name	Gene.ID	Gene	Compared t	o control_heal	thy group	Compared	to control_smo	kers group	Ref*	5	2	ε.		
		type	log2Fold- Change	p-value	p-adj	log2Fold- Change	p-value	p-adj		%Detected; %CV <sup>1</sup>	%Detected; %CV <sup>2</sup>	%Detected; %CV <sup>3</sup>	Differentially Ex- pressed in Stage 1?	Differentially Ex- pressed in Stage 2?
ENSG00000102970	CCL17	protein coding	8.7116	1.5x10^-04	5.2x10^-03	9.1579	5.0x10^-05	1.1x10^-02	[28-30]	27.23; 42.76	25.00; 30.72	41.67; 56.66	-	-
ENSG0000104880	ARHGEF18	Protein coding	7.2400	4.6x10^-11	1.4x10^-08	4.2579	4.7x10^-05	1.1x10^-02	[31]	81.82; 27.96	91.67; 20.43	91.67; 45.07	Vs Control Healthy	
ENSG00000123892	RAB38	protein coding	-5.6801	1.0x10^-03	1.9x10^-02	-6.8853	4.6x10^-05	1.0x10^-02	[32, 33]	54.55; 45.28	66.67; 48.13	41.67; 26.48		Vs. both controls
ENSG00000178104	PDE4DIP	protein coding	-5.3701	1.9x10^-04	6.3x10^-03	-5.2635	1.9x10^-04	3.0x10^-02	[34, 35]	63.64; 43.90	83.33; 36.32	50.00; 15.50	Vs. Control Healthy	
ENSG0000259571	BLID	protein coding	-6.4355	3.0x10^-03	3.7x10^-02	-10.4897	7.4x10^-07	3.1x10^-04	[36]	18.18; 33.91	58.33; 53.16	33.33; 4.89	Vs. Control Smokers	
ENSG00000271303	SRXN1	protein coding	-4.8705	3.3x10^-03	3.9x10^-02	-5.9253	2.5x10^-04	3.7x10^-02	[37-39]	54.55; 54.83	66.67; 47.06	41.67; 27.08	-	-
ENSG00000207586	MIR135A2	miRNA	-19.6805	2.1x10^-12	8.9x10^-10	-25.9452	1.5x10^-21	3.3x10^-18	[40, 41]	18.18; 51.99	41.67; 44.96	8.33; 40.13	Vs. both controls	Vs. both controls
ENSG00000207639	MIR193B	miRNA	-19.8578	4.3x10^-08	6.2x10^-06	-23.3468	4.0x10^-11	2.1x10^-08	[42-44]	18.18; 30.89	33.33; 52.06	8.33; 16.35	Vs. both controls	Vs. both controls
ENSG00000207647	MIR153-1	miRNA	-17.9600	1.9x10^-07	2.3x10^-05	-25.6172	1.4x10^-14	1.1x10^-11	[45-48]	18.18; 26.33	33.33; 57.10	16.67; 53.34	-	-
ENSG00000207763	MIR617	miRNA	22.1588	8.9x10^-10	1.8x10^-07	26.8981	2.8x10^-14	2.0x10^-11	[49]	9.09; 33.09	0;0	33.33; 41.96	Vs. both controls	Vs. both controls
ENSG00000207863	MIR125B2	miRNA	12.9574	1.0x10^-05	7.3x10^-04	-10.2390	2.7x10^-04	3.8x10^-02	[50-52]	9.09; 31.19	41.67; 51.38	16.67; 32.68	-	-
ENSG00000221552	MIR1303	miRNA	23.9859	3.3x10^-11	1.1x10^-08	39.7024	2.8x10^-29	1.8x10^-25	[31, 35]	9.09; 37.13	0;0	33.33; 59.01	-	-
ENSG00000200478	SNORD115- 41	snoRNA	-14.1259	1.2x10^-05	8.3x10^-04	-37.1348	3.8x10^-33	1.2x10^-28	[22]	9.09; 14.02	33.33; 43.45	0;0	**	**
ENSG00000212304	SNORD12	snoRNA	-22.5404	4.4x10^-10	1.0x10^-07	-22.3897	2.4x10^-10	1.2x10^-07	[22]	18.18; 68.86	25.00; 40.72	0;0	Vs. both controls	Vs. both controls

#### *Diagnostics* **2022**, *12*, x FOR PEER REVIEW

									[53-55]	63.64;	83.33;	83.33;	Vs.	Vs. both
		processed								43.01	44.07	46.29	Control	controls
ENSG00000255717	SNHG1	transcript	-4.2180	1.4x10^-03	2.3x10^-02	-5.2295	5.0x10^-05	1.1x10^-02					smokers	

\*References for studies on lung biopsies; p-adj: p-value adjusted for multiple corrections based on the number of total detected cfRNA transcripts; %Detected – percentage of 264 samples in which the transcripts were detected above threshold; <sup>1</sup>control\_healthy; <sup>2</sup>control\_smokers; <sup>3</sup>combined cases; \*\*expressed in opposite direction (upregulated) in con-265 trol\_smokers 266

11 of 18

267

perpetuity. It is made available under a CC-BY-ND 4.0 International license .



MDPI

268

295

296

Gene ontology (GO) enrichment analysis of differentially expressed cfRNA: The unbiased pathway 269 analysis with cfRNA for the differentially expressed genes included in each category of Figure 1.1 re-270 vealed 123 significantly enriched pathways across the three comparison groups. The cases compared 271 to control smokers had one significantly enriched pathway that was also detected in cancer-free smok-272 ers; GO:0010629 (negative regulation of gene expression) with 286 cfRNA in control\_smokers vs con-273 trol\_healthy group (adjusted p= 0.0041) and 24 cfRNA in cases vs control\_smokers group (adjusted p= 274 5.98E-05). However, at an individual gene level, only 2 cfRNA (MIR874 and MIR551B) in GO:0010629 275 were common to the 2 groups, both in terms of direction and type. The cases vs control\_smokers and 276 cases vs control\_healthy comparisons did not share any significantly enriched pathways. Eighty-five 277 pathways were commonly enriched in cases and cancer-free smokers when each group was compared 278 with the control\_healthy. Details of the 37 pathways that were uniquely enriched in cases compared 279 with both control groups include general mechanisms underlying cancer biology and are presented in 280 Table 3 below. The gene IDs for cfRNA enriched within these pathways are listed in Supplementary 281 Table 2. 282

Twenty five of 37 uniquely enriched pathways in cases were in comparison to the non-283 smoking control group, of which 20 were in the GO domain of biological process (BP) and five in the 284 domain molecular function (MF). For BP domain the significant terms were: GO:0001501, GO:0007186, 285 GO:0007200, GO:0008154, GO:0009888, GO:0009953, GO:0007399, GO:0010454, GO:0032501, 286 GO:0042692, GO:0043403, GO:0043503, GO:0042221, GO:0042246, GO:0045165, GO:0051272, 287 GO:0051493, GO:1902903, GO:1904888, and GO:2001046. For MF domain the significant terms were: 288 GO:0005125, GO:0005198, GO:0019958, GO:0030545, and GO:0048018. The remaining 12 of the 37 path-289 ways uniquely enriched in cases were in comparison to cancer-free smokers. These were in BP (N=7), 290 MF (N=2) and cellular component (CC; N=3) domains. For BP domain the significant terms were: 291 GO:0010608, GO:0016441, GO:0016458, GO:0031047, GO:0035194, GO:0035195, and GO:0040029. For 292 MF domain the significant terms were: GO:0003729 and GO:1903231. For CC domain the significant 293 terms were: GO:0016442, GO:0031332, and GO:1990904. 294

ID	Description of pathway	Gene ratio	p-value	p-adjust
Cases vs. cor	trol_healthy:		_	
GO:0001501	skeletal system development	71/1685	8.5591E-05	0.016903
GO:0005125	cytokine activity	42/1656	6.6270E-05	0.022704
GO:0005198	structural molecule activity	105/1656	2.0920E-05	0.009907
GO:0007186	G protein-coupled receptor signaling	179/1685	5.2099E-06	0.002827
GO:0007200	phospholipase C-activating G protein-coupled receptor signaling	22/1685	4.5649E-05	0.011269
GO:0007399	nervous system development	258/1685	0.0003	0.037022
GO:0008154	actin polymerization or depolymerization	34/1685	0.0004	0.046481
GO:0009888	tissue development	248/1685	1.0524E-06	0.001336
GO:0009953	dorsal/ventral pattern formation	19/1685	0.0003	0.044695
GO:0010454	negative regulation of cell fate commitment	7/1685	2.6616E-05	0.007885
GO:0019958	C-X-C chemokine binding	5/1656	2.3133E-05	0.009907
GO:0030545	receptor regulator activity	85/1656	2.1418E-06	0.002111
GO:0032501	multicellular organismal process	802/1685	2.1589E-06	0.002132
GO:0042221	response to chemical	513/1685	0.0001	0.018405
GO:0042246	tissue regeneration	17/1685	0.0002	0.027754

Table 3: Enriched pathways in cases compared to the two control groups

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

*Diagnostics* **2022**, *12*, x FOR PEER REVIEW

		1		
GO:0042692	muscle cell differentiation	55/1685	0.0003	0.037022
GO:0043403	skeletal muscle tissue regeneration	11/1685	0.0003	0.044909
GO:0043503	skeletal muscle fiber adaptation	4/1685	4.4531E-05	0.011269
GO:0045165	cell fate commitment	46/1685	1.9621E-05	0.006707
GO:0048018	receptor ligand activity	79/1656	2.4643E-06	0.002111
GO:0051272	positive regulation of cellular component movement	84/1685	7.8914E-06	0.003597
GO:0051493	regulation of cytoskeleton organization	73/1685	0.00012	0.020485
GO:1902903	regulation of supramolecular fiber organization	51/1685	0.0004	0.047617
GO:1904888	cranial skeletal system development	15/1685	0.0003	0.044566
GO:2001046	positive regulation of integrin-mediated signaling	5/1685	6.6284E-05	0.014261
Cases vs. con	trol_smokers:			
GO:0003729	mRNA binding	23/81	1.0069E-05	0.001057
GO:0010608	posttranscriptional regulation of gene expression	23/81	3.0028E-10	4.69E-08
GO:0016441	posttranscriptional gene silencing	22/84	4.4483E-15	1.62E-12
GO:0016442	RISC complex	23/81	7.5451E-17	6.64E-15
GO:0016458	gene silencing	23/81	1.5066E-13	3.29E-11
GO:0031047	gene silencing by RNA	22/84	1.2005E-14	3.28E-12
GO:0031332	RNAi effector complex	23/81	7.5451E-17	6.64E-15
GO:0035194	posttranscriptional gene silencing by RNA	23/81	4.3205E-15	1.62E-12
GO:0035195	gene silencing by miRNA	23/81	3.2204E-15	1.62E-12
GO:0040029	regulation of gene expression, epigenetic	23/81	7.5803E-13	1.38E-10
GO:1903231	mRNA binding involved in posttranscriptional gene silencing	23/84	2.5252E-08	5.3E-06
GO:1990904	ribonucleoprotein complex	23/84	1.9793E-08	1.16E-06

Gene ratio – number of significant genes identified in the data set as a ratio of the total number of genes in a pathway.

#### 298 299

297

# 4. Discussion

Various subtypes of circulating cfRNA have been tested in plasma for early-stage detection of 301 NSCLC. Building upon these studies, we performed a comprehensive analysis of circulating plasma 302 cfRNA using next generation sequencing technologies to expand the repertoire of non-invasively meas-303 urable NSCLC signatures. We identified 2357 cfRNA enriched in 123 pathways in those with a diagno-304 sis of NSCLC compared to control groups consisting of cancer-free smokers and non-smokers. Nearly 305 half of the detected cfRNA were transcripts of protein coding genes, and 251 of 2357 cfRNA (10.65%) 306 conformed to previously reported differentially expressed genes in primary tumor biopsies from 307 NSCLC patients. A majority (174 of 251) of these replicated transcripts were protein coding genes, while 308 the rest were previously reported miRNA and other non-coding RNAs. In fact, two of the snoRNAs -309 SNORD115-41 and SNORD12, were previously reported in NSCLC tissue biopsies by our group [22]. 310

Importantly, our pilot study used a workflow that can be easily adopted to develop a clinical assay 311 for profiling cfRNA using plasma volumes smaller than that were reported elsewhere[56]. The archived 312 plasma samples were derived from whole blood collected in standard 3-6 ml EDTA collection tubes 313 routinely used in clinical care. Processing of small amounts of plasma (approximately 1.5ml) yielded 314 less than 5ng of total cfRNA, and library preparation with enrichment and sequencing was carried out 315 for efficient identification of cfRNA. Our methodology produced 200 to 350 million of sequence reads 316

Diagnostics 2022, 12, x FOR PEER REVIEW

14 of 18

per sample, with over 80% of reads mapping to exonic regions of the reference, comparable to what is 317 reported in methods that required much higher volumes of plasma [57]. 318

Although identifying biomarker signatures associated with NSCLC was not the primary 319 objective of this proof-of-concept pilot study that sought to test the potential of an NGS-based method 320 for comprehensive detection of circulating cfRNA in plasma, we further evaluated cfRNA of the 251 321 genes to explore potential candidates for future NSCLC associated biomarker development studies. We 322 first searched for cfRNA that were differentially expressed in plasma samples from NSCLC patients 323 (regardless of the subtypes) compared to both smokers with benign PNs and non-smokers. Our results 324 indicated 15 genes that included six protein coding, six miRNA and three other non-coding genes. 325 Twelve of the 15 genes had low inter-patient variability (i.e., CV <50%) for cfRNA expression. These 326 included five cf-mRNA (ARHGEF18, RAB38, PDE4DIP, BLID, and SRXN1), four cf-miRNA 327 (MIR135A2, MIR193B, MIR617, MIR125B2), and all three of the other non-coding genes (SNORD115-328 41, SNORD12, SNHG1). Notably, cfRNA for the two snoRNAs SNORD115-41 and SNORD12 genes 329 which we have reported previously[22], were not detectable in any NSCLC sample, but were present 330 in both control groups with low inter-subject variability, confirming their potential role as plasma bi-331 omarkers of NSCLC. Furthermore, identifying protein coding genes (i.e., cf-mRNA) with low inter-332 patient variability was particularly significant as studies on circulating cf-mRNA are relatively sparse 333 compared to miRNA or other non-coding genes. Thus, we tested the differential expression of the five 334 cf-mRNA associated with NSCLC in a different cohort of NSCLC patients, smokers with benign PN, 335 and non-smokers using quantitative RT-PCR. Our results indicated differential expression of cfRNA 336 for ARHGEF18, PDE4DIP, and SRXN1 genes, but not RAB38 and BLID. The ARHGEF18 (Rho/Rac Gua-337 nine Nucleotide Exchange Factor 18) also known as P114-RhoGEF activates the downstream gene RhoA 338 which is important for cell migration and tumor progression[58, 59]. Song et al. showed that 339 ARHGEF18 gene was upregulated in squamous-cell carcinoma compared to adenocarcinoma or non-340 tumor tissue, and significantly associated with lung cancer lymph node metastasis[31]. In line with 341 these findings, we detected an upregulation of ARHGEF18 in our discovery cohort (Figure 3 and Table 342 2), but a downregulation in the validation sample (Figure 4). It is possible that the reversal in direction 343 of expression levels in the validation cohort occurred due to suboptimal qRT-PCR assay conditions as 344 described below, rather than due to biological differences. The PDE4DIP (Phosphodiesterase 4D Inter-345 acting Protein) that anchors phosphodiesterase in centrosomes[35] was shown to co-express with the 346 endogenous tumor suppressor gene THBS1, and high expression levels of PDE4DIP were associated 347 with improved survival rates in adenocarcinoma patients[34]. Additionally, an exome-wide study of 348 peripheral blood samples identified a frame-shift mutation in PDE4DIP of cancer patients but not in 349 cancer-free family members suggesting a possible association of PDE4DIP with development of squa-350 mous cell lung cancer[35]. The SRXN1 (Sulfiredoxin 1) - another phosphodiesterase 4D anchoring pro-351 tein, was found to be upregulated in lung cancer cell lines A549 and 95D and 75 NSCLC tissues com-352 pared to the adjacent non-tumor tissue. In our study both PDE4DIP and SRXN1 were downregulated 353 in the discovery and validation cohorts[39]. More studies are needed to characterize the directionality 354 associated with clinical characteristics of NSCLC development and progression. 355

Our pilot study has several limitations. First, biological factors such as gender and age have been 356 shown to play a major role in the development and prognosis of lung cancers [60]. For example, women 357 smokers have greater risk for developing lung cancer compared to men who smoke, presumably due 358 to underlying genetic and other biological differences between men and women [61, 62]; the AC sub-359 type predominates in women, whereas SCC are more common in men [63]; and individuals aged 65 360 and older are at greater risk of developing lung cancers[60]. The over-representation of samples from 361 male patients as compared to the two control groups, and the modest sample size in this pilot project 362 limited our ability to explore moderating effects of these biological factors on our findings. This is par-363 ticularly true of the subtype analyses that revealed 452 differentially expressed cfRNA between AC and 364 SCC groups, and 1,075 between stages I and II that consisted of small numbers of patients. Second, both 365 groups of smokers - with and without cancer, were significantly older than the non-smoking control 366 group in the discovery cohort. The larger numbers of DEGs that we detected in comparisons of NSCLC 367 patients and non-cancer smokers with non-smokers may possibly have arisen from confounding effects 368

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

*Diagnostics* **2022**, *12*, x FOR PEER REVIEW

15 of 18

389

of age-related alterations in expression of genes (see Figure 1.1). However, we were able to validate 369 three out of five selected genes tested in an independent cohort with a balanced age distribution be-370 tween comparison groups. Third, because of lack of information on stable endogenous reference 371 gene(s) for the normalization of qRT-PCR data for circulating mRNA, we conducted validation analyses 372 for the subset of five genes without the use of an endogenous control. Systematic analyses are urgently 373 required to identify candidate genes with stable expression levels of cf-mRNA across samples for con-374 tinued research on cf-mRNA analysis in NSCLC. Perhaps large RNA-seq data sets on circulating tran-375 scriptomes in plasma from NSCLC patients could facilitate such analyses. Fourth, we were not able to 376 test the tissue specificity of the identified cfRNA because of the unavailability of lung tissue biopsies 377 from the included participants for direct comparisons with plasma cfRNA. Nevertheless, we have uti-378 lized two control groups to adjust for confounding effects of smoking on cfRNA expression levels and 379 applied conservative statistical thresholds of 5% FDR and a minimum of 2-fold change difference in 380 expression level between conditions to reduce false positive findings. Furthermore, the fact that we 381 were able to detect cfRNA of hundreds of previously reported RNA transcripts from primary NSCLC 382 biopsies, is indeed promising. 383

In summary, we have presented transcriptome-wide cfRNA profiling using small volumes of 384 plasma providing a framework for developing a non-invasive (blood-based) assay for potential early 385 detection, diagnosis, and monitoring of NSCLC to facilitate high rates of patients able to receive curative surgical resections. Further studies are required for evaluation of our methodology and its clinical 387 application. 388

**Supplementary Materials:** The following supporting information can be downloaded at: [...], 390 Supplementary Table 1: Differentially expressed cfRNA 391 Supplementary Table 2: Genes included in enriched pathways 392 Supplementary Figure 1: qRT-PCR analysis of spike-in controls for cfRNA isolation across samples 393 394 Author Contributions: Conceptualization, C.S., A.C.S., F.J., K.M. and S.F.; methodology, C.S., A.C.S., F.J., and S.F.; 395 formal analysis, A.C.S. and C.M.; resources, X.X.; data curation, C.S., A.C.S., X.G., C.M. and J.C.; writing-original 396 draft preparation, C.S.; writing-review and editing, A.C.S., F.J., K.M. and S.F.; supervision, C.S., A.C.S., F.J., and 397 S.F.; funding acquisition, S.F.. All authors have read and agreed to the published version of the manuscript 398 Funding: This research was funded by NCI-U24CA11509-01 (SS), FDA-5U01FD005946-06(FJ), and NCI-399 UH2CA229132 (FJ). 400 Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki 401 and approved by the Institutional Review Board (or Ethics Committee) of the University of Maryland Baltimore 402 [UMB IRB protocol ID: HP-00040666] and the Veterans Affairs Maryland Health Care System [protocol ID: VA-403 00040666]. 404Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. 405 406 Acknowledgments: Authors would like to thank Dan Gheba and Tara Kesteloot for their expert advice with de-407 veloping the assays, John Sivinski for his assistance with sample processing, and Dr. Lisa Sadzewicz and Sandra 408 Ott for advice and assistance with two-step sequencing. 409 Conflicts of Interest: The authors declare no conflict of interest. 410 411 References 412 1. American Cancer Society. Facts & Figures 2022. American Cancer Society. Atlanta, Ga., 2022. 413 2. WHO global report on trends in prevalence of tobacco use 2000-2025. Fourth ed. 2021, Geneva: World Health 414

Organization.
3. Li, Y., et al., *Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer*416 *risk.* Hum Mol Genet, 2022.
417

4.	Besaratinia, A., A. Caceres, and S. Tommasi, <i>DNA Hydroxymethylation in Smoking-Associated Cancers</i> . Int J	418 419
F	Mol Sci, 2022. <b>23</b> (5).	
5.	Huang, Y., et al., <i>Air Pollution, Genetic Factors, and the Risk of Lung Cancer: A Prospective Study in the UK Biobank.</i> Am J Respir Crit Care Med, 2021. <b>204</b> (7): p. 817-825.	420 421
6.	Biotunik. And J Kespin Citt Care Med, 2021. 204(7). p. 617-625. Bade, B.C. and C.S. Dela Cruz, Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med,	421
0.	2020. 41(1): p. 1-24.	423
7.	Leduc, C., et al., Comorbidities in the management of patients with lung cancer. Eur Respir J, 2017. <b>49</b> (3).	423
8.	Campling, B.G., et al., Spontaneous smoking cessation before lung cancer diagnosis. J Thorac Oncol, 2011. <b>6</b> (3):	424
0.	p. 517-24.	426
9.	Siegel, R.L., et al., <i>Cancer Statistics</i> , 2021. CA Cancer J Clin, 2021. <b>71</b> (1): p. 7-33.	427
10.	Force., U.S.P.S.T., Final Update Summary: Lung Cancer: Screening.	428
	https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-	429
	<u>screening.</u> , July 2015.	430
11.	Force, U.S.P.S.T., et al., Screening for Lung Cancer: US Preventive Services Task Force Recommendation	431
	Statement. JAMA, 2021. <b>325</b> (10): p. 962-970.	432
12.	Jonas, D.E., et al., Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report	433
	and Systematic Review for the US Preventive Services Task Force. JAMA, 2021. <b>325</b> (10): p. 971-987.	434
13.	Tanner, N.T., et al., Management of Pulmonary Nodules by Community Pulmonologists: A Multicenter	435
	<i>Observational Study.</i> Chest, 2015. <b>148</b> (6): p. 1405-1414.	436
14.	Pinzani, P., et al., Updates on liquid biopsy: current trends and future perspectives for clinical application in solid	437
	<i>tumors</i> . Clin Chem Lab Med, 2021. <b>59</b> (7): p. 1181-1200.	438
15.	Li, R.Y. and Z.Y. Liang, Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and	439
	treatment response. Chin Med J (Engl), 2020. 133(20): p. 2476-2485.	440
16.	Gale, D., et al., Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell	441
	<i>lung cancer</i> . Ann Oncol, 2022. <b>33</b> (5): p. 500-510.	442
17.	Larson, M.H., et al., A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-	443
	specific biomarkers for cancer detection. Nat Commun, 2021. <b>12</b> (1): p. 2357.	444
18.	Sorber, L., et al., Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation	445
	Protocol. Cancers (Basel), 2019. 11(4).	446
19.	Muller, S., et al., Circulating MicroRNAs as Potential Biomarkers for Lung Cancer. Recent Results Cancer Res,	447
	2020. <b>215</b> : p. 299-318.	448
20.	de Fraipont, F., et al., Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic	449
	Response in the Liquid Biopsies of Lung Cancer Patients. Front Genet, 2019. 10: p. 390.	450
21.	Peng, W., et al., Diagnostic and Prognostic Potential of Circulating Long Non-Coding RNAs in Non Small Cell	451
	Lung Cancer. Cell Physiol Biochem, 2018. 49(2): p. 816-827.	452
22.	Gao, L., et al., Genome-wide small nucleolar RNA expression analysis of lung cancer by next-generation deep	453
	<i>sequencing</i> . Int J Cancer, 2015. <b>136</b> (6): p. E623-9.	454
23.	https://www.illumina.com/products/by-type/sequencing-kits/library-prep-kits/rna-prep-	455
	enrichment.html.	456
24.	Shetty, A.C., et al., CAVERN: Computational and visualization environment for RNA-seq analyses. 69th Annual	457
	Meeting. Houston, Texas: American Society of Human Genetics., 2019.	458

25.	Kim, D., et al., <i>Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype</i> . Nat Biotechnol, 2019. <b>37</b> (8): p. 907-915.	459 460
26.	Anders, S., P.T. Pyl, and W. Huber, HTSeqa Python framework to work with high-throughput sequencing data.	461
	Bioinformatics, 2015. <b>31</b> (2): p. 166-9.	462
27.	Benjamini, Y. and Y. Hochberg, Controlling the False Discovery Rate: A Practical and Powerful Approach to	463
	Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological), 1995. 57(1): p. 289–300.	464
28.	Yamashita, S., et al., Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-	465
	small cell lung cancer. J Exp Clin Cancer Res, 2009. 28: p. 22.	466
29.	Ye, T., et al., Chemokine CCL17 Affects Local Immune Infiltration Characteristics and Early Prognosis Value of	467
	Lung Adenocarcinoma. Front Cell Dev Biol, 2022. 10: p. 816927.	468
30.	Yang, J., et al., Circular RNA CHST15 Sponges miR-155-5p and miR-194-5p to Promote the Immune Escape of	469
	Lung Cancer Cells Mediated by PD-L1. Front Oncol, 2021. 11: p. 595609.	470
31.	Song, C., et al., Expression of p114RhoGEF predicts lymph node metastasis and poor survival of squamous-cell	471
	lung carcinoma patients. Tumour Biol, 2013. 34(3): p. 1925-33.	472
32.	Hsieh, J.J., et al., RAB38 is a potential prognostic factor for tumor recurrence in non-small cell lung cancer. Oncol	473
	Lett, 2019. <b>18</b> (3): p. 2598-2604.	474
33.	Chang, J.W., et al., Comparison of genomic signatures of non-small cell lung cancer recurrence between two	475
	<i>microarray platforms</i> . Anticancer Res, 2012. <b>32</b> (4): p. 1259-65.	476
34.	Weng, T.Y., et al., Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and	477
	a Systematic-Analysis of Microarray Databases. PLoS One, 2016. 11(8): p. e0161007.	478
35.	Li, S., et al., Sequencing study on familial lung squamous cancer. Oncol Lett, 2015. 10(4): p. 2634-2638.	479
36.	Wang, H., et al., Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK	480
	signaling pathways in non-small cell lung cancer. Int J Biochem Cell Biol, 2018. 94: p. 98-106.	481
37.	Li, Z., et al., miRNA-124 modulates lung carcinoma cell migration and invasion. Int J Clin Pharmacol Ther,	482
	2016. <b>54</b> (8): p. 603-12.	483
38.	Wei, Q., et al., Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation	484
	of specific phosphokinase signaling. Proc Natl Acad Sci U S A, 2011. <b>108</b> (17): p. 7004-9.	485
39.	Zhou, J., et al., Identification of SRXN1 and KRT6A as Key Genes in Smoking-Related Non-Small-Cell Lung	486
	Cancer Through Bioinformatics and Functional Analyses. Front Oncol, 2021. 11: p. 810301.	487
40.	Zhang, Y., et al., ARID1A is downregulated in non-small cell lung cancer and regulates cell proliferation and	488
	<i>apoptosis</i> . Tumour Biol, 2014. <b>35</b> (6): p. 5701-7.	489
41.	Wang, N. and T. Zhang, Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer	490
	to Gefitinib by Targeting TRIM16. Oncol Res, 2018. 26(7): p. 1005-1014.	491
42.	Hu, F., et al., Lung adenocarcinoma resistance to therapy with EGFRtyrosine kinase inhibitors is related to	492
	increased expression of cancer stem cell markers SOX2, OCT4 and NANOG. Oncol Rep, 2020. <b>43</b> (2): p. 727-735.	493
43.	Choi, K.H., et al., Dual-strand tumor suppressor miR-193b-3p and -5p inhibit malignant phenotypes of lung	494
	<i>cancer by suppressing their common targets.</i> Biosci Rep, 2019. <b>39</b> (7).	495
44.	She, K., et al., miR-193b availability is antagonized by LncRNA-SNHG7 for FAIM2-induced tumour progression	496
	in non-small cell lung cancer. Cell Prolif, 2018. <b>51</b> (1).	497
45.	Chen, W.J., et al., MicroRNA-153 expression and prognosis in non-small cell lung cancer. Int J Clin Exp Pathol,	498
	2015. <b>8</b> (7): p. 8671-5.	499

46.	Yuan, Y., et al., Suppression of AKT expression by miR-153 produced anti-tumor activity in lung cancer. Int J	500
	Cancer, 2015. <b>136</b> (6): p. 1333-40.	501
47.	Zhang, W., et al., Expressions of connexin 32 and 26 and their correlation to prognosis of non-small cell lung	502
	<i>cancer</i> . Ai Zheng, 2009. <b>28</b> (2): p. 173-6.	503
48.	Shan, N., et al., MiR-153 inhibits migration and invasion of human non-small-cell lung cancer by targeting	504
	ADAM19. Biochem Biophys Res Commun, 2015. 456(1): p. 385-91.	505
49.	Kim, H.K., et al., miR-592 and miR-552 can distinguish between primary lung adenocarcinoma and colorectal	506
	cancer metastases in the lung. Anticancer Res, 2014. 34(5): p. 2297-302.	507
50.	Huang, S.P., et al., Downregulation of miR-125b-5p and Its Prospective Molecular Mechanism in Lung Squamous	508
	Cell Carcinoma. Cancer Biother Radiopharm, 2022. 37(2): p. 125-140.	509
51.	Wang, J., et al., Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer. Tumour	510
	Biol, 2015. <b>36</b> (9): p. 6965-72.	511
52.	Wang, M., et al., High expression of kinesin light chain-2, a novel target of miR-125b, is associated with poor	512
	clinical outcome of elderly non-small-cell lung cancer patients. Br J Cancer, 2015. 112(5): p. 874-82.	513
53.	Zhou, Q., et al., A novel lncRNA-miRNA-mRNA competing endogenous RNA regulatory network in lung	514
	adenocarcinoma and kidney renal papillary cell carcinoma. Thorac Cancer, 2021. 12(19): p. 2526-2536.	515
54.	Tan, J., et al., Integrative Analysis of Three Novel Competing Endogenous RNA Biomarkers with a Prognostic	516
	Value in Lung Adenocarcinoma. Biomed Res Int, 2020. 2020: p. 2837906.	517
55.	Shi, S.L. and Z.H. Zhang, Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell	518
	lung cancer by regulating miR-140-5p/Wnt/beta-catenin pathway. Neoplasma, 2019. <b>66</b> (5): p. 756-765.	519
56.	Mullins, K., et al., Proof of Concept: detection of cell free RNA from EDTA plasma in patients with lung cancer	520
	and non-cancer patients. medRxiv, 2022: p. 2022.08.12.22278721.	521
57.	Rasmussen, M., et al., RNA profiles reveal signatures of future health and disease in pregnancy. Nature, 2022.	522
	<b>601</b> (7893): p. 422-427.	523
58.	Terry, S.J., et al., Stimulation of cortical myosin phosphorylation by p114RhoGEF drives cell migration and tumor	524
	<i>cell invasion</i> . PLoS One, 2012. 7(11): p. e50188.	525
59.	Kim, M., et al., p114RhoGEF governs cell motility and lumen formation during tubulogenesis through a ROCK-	526
	<i>myosin-II pathway.</i> J Cell Sci, 2015. <b>128</b> (23): p. 4317-27.	527
60.	Leiro-Fernandez, V., et al., <i>Predicting delays in lung cancer diagnosis and staging</i> . Thorac Cancer, 2019. <b>10</b> (2):	528
	p. 296-303.	529
61.	Hellyer, J.A. and M.I. Patel, Sex disparities in lung cancer incidence: validation of a long-observed trend. Transl	530
	Lung Cancer Res, 2019. 8(4): p. 543-545.	531
62.	Molina, A.J., et al., <i>Trends in Lung Cancer Incidence in a Healthcare Area</i> . Arch Bronconeumol, 2015. <b>51</b> (11):	532
	p. e53-5.	533
63.	Pesch, B., et al., Cigarette smoking and lung cancerrelative risk estimates for the major histological types from a	534
	pooled analysis of case-control studies. Int J Cancer, 2012. <b>131</b> (5): p. 1210-9.	535
		536